Seeking Alpha

JPMorgan tries to make sense out of all the drama with MAP Pharmaceuticals (MAPP), by taking the...

JPMorgan tries to make sense out of all the drama with MAP Pharmaceuticals (MAPP), by taking the long view that Levadex is an "attractive, approvable product" despite missing out on first-pass FDA approval. Shares have been on a roller coaster ride since the FDA issued a complete response letter after the market closed yesterday, sitting as high as +7% and as low as -30% before settling back to trade -18.3% premarket. Stay tuned.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|